Market Eyes LiveAmgen Inc (AMGN) Stock Rating & Analysis
MELANY's data-driven read on Amgen Inc · Biological Products, (No Diagnostic Substances).
Amgen is a biotechnology company developing human therapeutics. Its main products include the red blood cell boosters Epogen and Aranesp, the immune boosters Neupogen and Neulasta, Enbrel and Otezla for inflammatory diseases, the bone drugs Prolia/Xgeva (approved 2010) and Evenity (2019), and its first cancer therapy Vectibix (introduced 2006). The Onyx Pharmaceuticals acquisition added the oncology drug Kyprolis.
Why AMGN scores 68/100
MELANY scores Amgen Inc 68/100 by weighing eight factors. Here is how AMGN breaks down.
Whether the price looks cheap or expensive against earnings, growth, and peers.
- Forward P/E 17.4x, earnings growth accelerating
Margins, returns on capital, and balance-sheet strength.
- Gross margin 70%
- ROE 91%
Direction and relative strength of the recent share-price trend.
- Price +15.2% above 50-day MA
- 50-day MA above 200-day (golden cross zone)
History of beating or missing estimates, and where estimates are heading.
- Beat EPS estimates 4 of last 4 quarters
- Avg EPS beat +9%
What Wall Street price targets and revisions are signalling.
Near-term events that could move the stock.
Upside weighed against volatility and drawdown risk.
How the current rate and market regime suits this kind of company.
Key risks for AMGN
- High debt-to-equity ratio 4.9x, rate-sensitive balance sheet
- Trading near 52-week high, limited upside without new positive catalyst
Sector and theme context
Amgen Inc sits in the Healthcare sector theme, which MELANY currently rates 42/100 for strength. Theme strength feeds AMGN's momentum and catalyst factors above.
AMGN trade plan (members only)
MELANY has a full position plan for Amgen Inc: a smart entry zone, an alert level, position sizing, and quarterly review triggers. It unlocks free when you create an account.
How MELANY rates AMGN
MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. Amgen Inc's 68/100 reflects mature factor weighting for its profile. Position framework managed by score-based check-ins, not a fixed holding period.
Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.
Frequently asked questions about AMGN
Is Amgen Inc (AMGN) a buy?
As of 2026-08-21, MELANY rated Amgen Inc Favorable with a composite score of 68/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.
What is Amgen Inc's MELANY score?
Amgen Inc (AMGN) has a MELANY composite score of 68/100, combining valuation, business quality, price momentum, earnings track record, analyst sentiment, catalyst setup, risk-adjusted profile, and macro fit.
How is the AMGN stock rating calculated?
MELANY scores AMGN from 0 to 100 across eight weighted factors using live market and fundamental data, then refreshes the rating automatically as new data arrives.
Should I buy Amgen Inc stock?
That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates Amgen Inc (AMGN) Favorable with a composite of 68/100 as of 2026-08-21. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.
What is the AMGN stock price forecast?
MELANY does not publish price targets or forecasts for AMGN. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 68/100 across eight factors for Amgen Inc, and re-scores automatically as new price, earnings, and fundamental data arrive.
Is AMGN stock overvalued or undervalued?
MELANY's valuation factor currently reads 42/100 for Amgen Inc, where a higher score means the price looks more attractive against earnings, growth, and peers. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives AMGN's read.
What price should I buy AMGN at?
Rather than chasing the current price, MELANY computes a smart entry zone for AMGN: the price area where risk and reward actually favor a new position, plus an alert level and position sizing. The exact levels unlock free when you create a Market Eyes Live account.
What are the risks of buying AMGN stock?
The top risks MELANY currently flags for Amgen Inc: High debt-to-equity ratio 4.9x, rate-sensitive balance sheet; Trading near 52-week high, limited upside without new positive catalyst. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.
Is Amgen Inc a good long-term investment?
For long-term durability the two factors that matter most are business quality, which MELANY scores 75/100 for Amgen Inc, and earnings track record, at 88/100. The 68/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.
Will AMGN stock go up?
Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 82/100 for AMGN right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.
How current is this AMGN rating?
The rating on this page is a snapshot of MELANY's read as of 2026-08-21. The price shown updates live, but the score is not recomputed on this page. MELANY re-scores AMGN continuously as new price, earnings, and fundamental data arrive, and that current rating is free in the app.
AMGN's entry zone, live alerts, and full trade plan are free either way. The app is our flagship.